LOS ANGELES—Lensabl has raised $3 million in series seed funding to grow its prescription lens replacement business. The round was led by Rogue Venture Partners, which recently led the funding of Sightbox, the contact lens subscription business acquired by Johnson & Johnson in 2017. Other investors in the round include Birchmere, Aspect Ventures, Cherry Tree Capital, Amplify.LA, Luma Launch, Watertower Ventures, and Crowdsmart. This brings Lensabl's total funding to $3.7 million, Lensabl CEO Andrew Bilinsky told VMAIL.

“We are excited to use this new funding to enhance the user experience for our customers,” said Bilinsky. “From the product offering, to the production and shipping times of the lenses, to customer service. Lensabl has grown 400 percent year over year, generating tons of great user data. We will use this data to offer a more personalized and seamless experience for our customers. At our core, we believe that everyone should have affordable and convenient access to customize their vision however they see fit.”

Since launching in late 2016, Lensabl has significantly expanded its range of products and services. Bilinsky said the company now works with Essilor labs and offers a wide range of Essilor lens products, including, but not limited to, clear, tinted, Transitions, and blue light blocking lenses.

In April, 2018, Lenabl began offering online vision tests through Opternative for customers to validate or update their prescription. The company also expanded its management team with the recent addition Andrew Germer as director of growth and marketing. Germer, an optical industry veteran, previously held a similar role at Sightbox.